Gamma Vaccines is developing GammaFlu®, a universal flu vaccine that is expected to do away with the need to produce new influenza vaccines each year. GammaFlu® is also being designed to be effective against any new pandemic strain, enabling it to be stockpiled and used as an immediate emergency response to any new influenza pandemic.
Gamma Vaccines manufactures and kills influenza virus in a manner that preserves the proper structure of the virus and its various proteins. By using gamma irradiation – a procedure in wide-spread use to sterilize surgical instruments and stop spoilage of perishable fruits – a killed virus preparation can be obtained that is no longer infectious and which induces a potent immunity to different influenza virus strains and subtypes.
Read More
About us
Gamma Vaccines Pty Ltd is an Australian company targeting primarily the human and avian influenza market.
Formed in July 2009, the company is developing a universal, cross-protective influenza virus vaccine, GammaFlu®, designed to replace current seasonal injectable flu vaccines with an easy-to-administer, long lasting intranasal vaccine. The Company’s products also hold the prospect of being able to be stockpiled for use as an immediate first response to any new influenza pandemic.
Gamma Vaccines’ proprietary technology was invented by leading viral immunologists from The Australian National University’s John Curtin School of Medical Research. The company has attracted seed investment funds and two early stage innovation grants from the federal government and the Australian Capital Territory government to support its development of a universal flu vaccine.
Founded by experienced early-stage managers and the inventors themselves, the company is currently negotiating with several partners in Asia and Europe to commence clinical trials for applications in both human and animal vaccination markets.
Recent News
- World Health
Organisation Conference| 17 November 2011GAMMA VACCINES MANAGEMENT TEAM GIVE KEY NOTE PRESENTATION TO THE WORLD HEALTH ORGANISATION CONFERENCE ON BROAD-SPECTRUM INFLUENZA VACCINES IN GENEVA - Additional New Director Appointed| 25 July 2011GAMMA VACCINES APPOINTS DR JEAN PETRE AS A NON-EXECUTIVE DIRECTOR.
- New Director Appointed| 22 June 2011GAMMA VACCINES APPOINTS DR KEN TEMPERO AS A NON-EXECUTIVE DIRECTOR.
- Follow-On Investment | 21 April 2011PT SOHO MAKES FOLLOW-ON INVESTMENT IN GAMMA VACCINES